Jove
Visualize
Contact Us

Related Experiment Videos

Early experience with sparfloxacin in tuberculosis.

S R Kamat1

  • 1Dattaguru Cooperative Housing Society, Deonar Village Road, Deonar, Mumbai-400 088.

The Journal of the Association of Physicians of India
|March 7, 2001
PubMed
Summary

This study found that oral Sparfloxacin showed early, dramatic responses in advanced tuberculosis patients. Most patients experienced good clinical and radiographic improvements with minimal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Down the memory lane: Lung India three decades.

Lung India : official organ of Indian Chest Society·2012
Same author

Comparative study of platelet histamine and serotonin with their corresponding plasma oxidases in asthmatics with normals.

The Journal of the Association of Physicians of India·2000
Same author

Effect of steam inhalation on mucociliary activity in patients of chronic pulmonary disease.

The Indian journal of chest diseases & allied sciences·1993
Same author

Air pollution related respiratory morbidity in central and north-eastern Bombay.

The Journal of the Association of Physicians of India·1992
Same author

Sequential respiratory, psychologic, and immunologic studies in relation to methyl isocyanate exposure over two years with model development.

Environmental health perspectives·1992
Same author

Objective thoracic CT scan findings in a Bhopal gas disaster victim.

Respiratory medicine·1991
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Advanced tuberculosis (TB) presents significant treatment challenges, particularly in patients with extensive prior treatment histories.
  • Exploring novel therapeutic agents is crucial for managing complex TB cases and improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of oral Sparfloxacin in patients with advanced tuberculosis.
  • To assess the response to Sparfloxacin in various forms of advanced TB, including bone disease and meningitis.

Main Methods:

  • A cohort of 14 advanced TB patients received oral Sparfloxacin 200 mg daily between December 1996 and July 1997.
  • Sparfloxacin was administered in combination with various standard anti-TB drugs, including PAS, isoniazid, rifampicin, doxycycline, pyrazinamide, ethambutol, and streptomycin.
  • Patient responses were monitored clinically, radiographically, and via sputum smear conversion.

Main Results:

  • An early and dramatic clinical response was observed in most patients treated with Sparfloxacin.
  • Twelve out of 14 patients showed good outcomes, with significant clinical improvement (11 patients), radiographic improvement exceeding 50% (11 patients), and sputum smear conversion (12 patients).
  • The primary side effect reported was nausea; one patient with tuberculous meningitis did not survive despite initial improvement.

Conclusions:

  • Oral Sparfloxacin demonstrated promising efficacy in treating advanced tuberculosis, including complex cases with abscesses and effusions.
  • The drug was generally well-tolerated, with nausea being the main adverse event.
  • Further investigation into Sparfloxacin's role in multidrug-resistant tuberculosis regimens may be warranted.

Related Experiment Videos